We are live on ! Find out more
BBH icon

VanEck Biotech ETF

52 hedge funds and large institutions have $112M invested in VanEck Biotech ETF in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,300% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 1

212% more call options, than puts

Call options by funds: $6.46M | Put options by funds: $2.07M

33% more funds holding

Funds holding: 3952 (+13)

21% more capital invested

Capital invested by funds: $91.9M → $112M (+$19.7M)

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

2.1% more ownership

Funds ownership: 21.31%23.41% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
52
Holders Change
+13
Holders Change %
+33.33%
% of All Funds
1.51%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
16
Reduced
14
Closed
1
Calls
$6.46M
Puts
$2.07M
Net Calls
+$4.39M
Net Calls Change
+$1.17M
Name Holding Trade Value Shares
Change
Change in
Stake
NCM
1
Niemann Capital Management
Nevada
$14M -$1.09M -13,060 -8%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$11M +$6.67M +79,801 +181%
CS
3
Credit Suisse
Switzerland
$9.78M +$877K +10,489 +10%
U
4
UBS
Switzerland
$9.48M -$908K -10,855 -9%
Citigroup
5
Citigroup
New York
$8.88M +$6.11K +73 +0.1%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$5.74M +$106K +1,262 +2%
Morgan Stanley
7
Morgan Stanley
New York
$5.01M -$152K -1,821 -3%
MCM
8
Murphy Capital Management
New Jersey
$4.87M +$1.25M +15,000 +37%
Goldman Sachs
9
Goldman Sachs
New York
$4.53M -$146K -1,750 -3%
AHS
10
Aspiriant Holdings S3
California
$3.72M +$99.9K +1,195 +3%
LFM
11
Lumina Fund Management
New York
$3.42M
CM
12
Churchill Management
California
$3.24M +$3.06M +36,569 New
AP
13
Advisors Preferred
Maryland
$2.74M +$2.59M +30,953 New
FMI
14
Factory Mutual Insurance
Massachusetts
$2.66M -$4.18M -50,000 -63%
LPL Financial
15
LPL Financial
California
$2.52M -$17.2K -206 -0.7%
AFG
16
Albion Financial Group
Utah
$1.97M -$26.8K -321 -1%
SFS
17
Strategic Financial Services
New York
$1.94M -$48.7K -582 -3%
ECML
18
Eagle Capital Management (Louisiana)
Louisiana
$1.67M +$1.58M +18,890 New
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$1.55M -$14.3K -171 -1%
Commonwealth Equity Services
20
Commonwealth Equity Services
Massachusetts
$1.41M -$232K -2,777 -15%
LTFS
21
Ladenburg Thalmann Financial Services
Florida
$1.1M -$83K -993 -7%
WJA
22
Williams Jones & Associates
New York
$1.01M -$309K -3,700 -25%
NES
23
New England Securities
New York
$949K +$871K +10,410 +3,305%
Bank of America
24
Bank of America
North Carolina
$914K -$401K -4,794 -32%
Ameriprise
25
Ameriprise
Minnesota
$763K +$28.4K +340 +4%

BBH Hedge Fund Activity: Q4 2013 in Review

52 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2013, worth a combined $112M — up 21% from $91.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new BBH positions and 1 closed out — a net gain of 13 holders — while 16 added to existing stakes and 14 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $6.67M. The largest seller was Factory Mutual Insurance, cutting an estimated $4.18M.

  • 52 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2013, up from 39 in Q3 2013.
  • Funds reported $112M of VanEck Biotech ETF stock for Q4 2013, up 21% quarter-over-quarter.
  • 14 funds opened new VanEck Biotech ETF positions in Q4 2013 and 1 closed out, a net change of +13 holders.
  • The largest VanEck Biotech ETF buyer in Q4 2013 was Susquehanna International Group, an estimated $6.67M added.
  • The largest VanEck Biotech ETF seller in Q4 2013 was Factory Mutual Insurance, an estimated $4.18M sold.

Based on aggregated 13F filings for Q4 2013.